Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Ever-Glory Updates Q2 Outlook - Quick Facts

RELATED NEWS
Trade EVK now with 
7/14/2012 11:13 AM ET

Ever-Glory International Group, Inc. (EVK: Quote), a leading apparel supply chain manager and retailer in China, provided an update regarding its Q2 financial results.

The total net sales for Q2 are anticipated in the range of $46 to $49 million versus prior guidance of $50 to $60 million, primarily because of the weaker-than-expected sales in the Company's retail segment.

Accordingly, the Company expects full-year 2012 sales in the range of $210 to 250 million versus prior guidance of $225 to $260 million.

Click here to receive FREE breaking news email alerts for Ever-Glory and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
U.K. retail sales rebounded at a faster-than-expected pace in May driven by food store sales, adding to evidence of economic recovery gaining firm footing in the second quarter. Sales volume including automotive fuel grew 2.1 percent in May from a month ago, when it was down 1.1 percent, figures released by the Office for National Statistics showed Thursday. The downturn in Eurozone's private sector economy eased sharply in May, but the improvement is unlikely to provide sufficient lift to the region's economy to avoid a further contraction in the second quarter. The Swiss National Bank on Thursday said it will retain the currency ceiling at CHF 1.2 per euro as risks to the economy from external developments remains high. The target range for the three-month Libor was also left unchanged at 0.0-0.25 percent. The decision was in line with economists' forecast. "Tensions can reappear at any moment on global financial markets," the central bank said.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.